Top Markets
#1 Islamic Coin Islamic Coin +151.50%
#2 DOVU DOVU +48.64%
#3 Akedo Akedo +46.30%
#4 Black Phoenix Black Phoenix +34.55%
#5 Velvet Velvet +32.25%
#6 DoubleZero DoubleZero +19.36%
#7 Cross Cross +16.34%
#8 Cap Cap +15.21%
#9 Tutorial Tutorial +13.37%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.43%
Coin of the day
Islamic Coin Islamic Coin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Clasificación en acciones #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Precio por acción
$17.15
Última sincronización: 2026-08-03
Capitalización bursátil
$6.51M
Cambio (1 día)
9.80%
Cambio (1 año)
289.77%
País
US
Comercio Galera Therapeutics, Inc. (GRTX)

Categoría

Healthcare
Ganancias de Galera Therapeutics, Inc. (GRTX)
Ganancias en Mar 2026 TTM: $149.04M
Secondo gli ultimi rapporti finanziari di Galera Therapeutics, Inc., gli utili attuali della società sono $149.04M. Nel 2023, la società ha registrato un utile di $-59.08M, un aumento con respecto a agli utili del 2022, che erano di $-62.29M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Galera Therapeutics, Inc. desde 2017 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $149.04M -877.84%
2024 $-19.16M -67.57%
2023 $-59.08M -5.15%
2022 $-62.29M -22.65%
2021 $-80.53M 8.49%
2020 $-74.23M 42.93%
2019 $-51.94M 117.33%
2018 $-23.90M -0.03%
2017 $-23.91M 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B 3,439.37%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B 1,208.85%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B 1,916.79%
BE